medigraphic.com

2020, Number S1

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2020; 58 (S1)

About possible medications to treat SARS-CoV-2 infection, which causes COVID-19. Is there any hope?

Torres-López J

Language: Spanish
References: 11
Page: 1-2
PDF size: 323.24 Kb.


ABSTRACT

To date, there is no treatment for patients infected with SARS-CoV-2. Several studies are being carried out in several countries and some have yielded promising results; however, still no effective treatment to combat COVID-19 has been identified, one of the most serious threats humanity has suffered in the last 100 years.


REFERENCES

  1. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020. DOI: 10.1056/NEJMoa2001282

  2. Wu CY, Jan JT, Ma SH, Kuo CJ, Juan HF, Cheng YSE et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. PNAS. 2004;101(27): 10012-7. DOI: 10.1073/pnas.0403596 101

  3. Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L et al. Treatment with Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. J Infect Dis. 2015;212(12): 1904-13. DOI: 10.1093/infdis/ jiv392

  4. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mahile M. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020. DOI: 10.1016/j.ijantimicag.2020.105949

  5. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. BioScience Trends. 2020;14(1):72- 73. DOI: 10.5582/bst.2020.01047

  6. Boulware D. Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP). Minneapolis, MN: University of Minnesota; 2020. 2 Disponible en: https://clinicaltrials.gov/ct2/show/ NCT04308668?cond=Coronavirus&cntry=US&state =US%3AMN&draw=2&rank=1

  7. Dalgard O. Norwegian Coronavirus Disease 2019 Study (NO COVID-19). Akhershus, Norway: Akerhus University Hospital; 2019. Disponible en: https://clinicaltrials.gov/ct2/show/NCT04316377?ter m=chloroquine+and+covid-19&draw=2&rank=3

  8. Schilling W. Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV). Oxford, UK: University of Oxford; 2020. Disponible en: https:// clinicaltrials.gov/ct2/show/NCT04303507?term=chl oroquine+and+covid-19&draw=2&rank=1

  9. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research.2020;30:269-271. Disponible en: https://www.nature.com/articles/ s41422-020-0282-0

  10. Retallack H, Di Lullo E, Arias C, Knopp KA, Laurie MT, Sandoval-Espinosa C et al. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci U S A. 2016; 113(50):14408-14413. Disponible en: https://www. ncbi.nlm.nih.gov/pubmed/27911847

  11. Madrid PB, Panchal RG, Warren TK, Shurtleft AC, Endsley AN, Green CE et al. Evaluation of Ebola Virus Inhibitors for Drug Repurposing. ACS Infect Dis. 2015; 1(7):317-26. DOI: 10.1021/acsinfecdis.5b00030




2020     |     www.medigraphic.com